Impax CEO’s Strategy: Aggressive BD, Restructure R&D And Cut Costs
This article was originally published in The Pink Sheet Daily
Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.
You may also be interested in...
Impax will gain 15 approved generics and three pipeline assets, which will help offset lower revenues of two of its existing top-sellers.
By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.
FDA dealt Impax Pharmaceuticals a “complete response” for its extended-release carbidopa/levodopa therapy for spasms suffered by Parkinson’s disease patients, rejecting the drug combo based on unresolved manufacturing issues at the firm’s Hayward, Calif., plant, though Impax has said it will manufacture the product, now called Rytary, exclusively at its Taiwan facility.